Contents:

Foreword Executive Summary France Introduction Key Data Projections, 2007-2012 Healthcare System Organisation Health Insurance System Health Expenditure Health Expenditure, 1995-2006 (Billion Euros) Medical Consumption by Service, 2000-2006 (Billion Euros) Spending Trends on Pharmaceuticals & Medical Products in the Ambulatory Sector, 1995-2005 (%) Medical Consumption by Source of Funding, 1995-2006 (%) Medical Consumption by Sector & Source of Funding, 2005 (%) Healthcare Infrastructure Hospital Resources Hospital Services, 1995-2005 Public Hospitals by Type, 2004 Private Hospitals by Type, 2005 Private Hospitals by Status, 2004 Hospital Beds & Day Places by Specialty & Sector, 2005 Hospital Activity Hospital Activity, 2001-2005 Hospital Activity by Specialty, 2005 Patient Distribution by Most Frequent Diagnostic Groups in Public & Private Hospitals, 2004 Inpatient Activity in Public Short-Stay Units by Major Diagnostic Groups, 2003 Inpatient Activity in Private Short-Stay Units by Major Diagnostic Groups, 2003 Ambulatory Resources Independent Practitioners by Type of Practice, 2002 (%) Medical Personnel Medical Personnel, 1995-2004 Doctors by Specialty & Sector, 2001-2003 Pharmaceutical Market Overview Size Summary of the French Pharmaceutical Market, 2007 Projections Market Projections, 2007-2012 Local Manufacturers Mergers & Acquisitions of French Pharmaceutical Companies, 1995-2007 Pharmaceutical Companies Operating in France Generic Market Size Reimbursable Market by Patent Status, 2002-2006 (Million Euros) Reimbursable Market by Patent Status, 2002-2006 (%) Change in Reimbursable Market by Patent Status, 2002-2006 (%) Reimbursable Market by Patent Status, 2002-2006 (Million Units) Reimbursable Market by Patent Status, 2002-2006 (%) Change in Reimbursable Market by Patent Status, 2003-2006 (%) Reimbursable Market by Substitution, 2006 Substitutable Market by Reimbursement Status, 2005-2006 (Million Euros) Subtitutable Market by Reimbursement Status, 2005-2006 (%) Projections Projected Generics Market, 2007-2012 (US$ Billion) Outlook Outcomes of the New Reference Pricing System Increasing Prescribing of Generics Generic Drugs to Reduce Health Expenditure by 912 Million Euros in 2006 Trends in Generic Drug Consumption, 2003-2006 France Transposes EU Pharmaceutical Directive Pharmacists Associations Agree New Generics Target for 2007 Generics Penetration Objectives by Volume, 2006 Generics Penetration Objectives by Volume, 2007 SWOT SWOT Analysis of the French Generics Market, 2007 Trade Association Members of GEMME, 2007 Domestic Production Leading French Generic Producers, 2005-2006 (%) Local Manufacturers Arrow Génériques Biogaran Bouchara-Recordati EG-Labo EG-Labo’s Sales, 2002-2006 (Million Euros) EG-Labo’s Sales as % of Stada’s Sales, 2002-2006 Merck Génériques Merck Génériques’ Financial Indicators, 2003-2006 Ranbaxy Ranbaxy Pharmacie Génériques’ Sales, 2004-2006 (US$ Million) ratiopharm ratiopharm France’s Sales, 2004-2006 (Million Euros) Sandoz Sandoz France’s Sales, 2001-2006 (Million Euros) Teva Winthrop Wockhardt Zydus France Zydus France’s Sales, 2003-2005 Regulatory Environment Registration Pricing & reimbursement Pricing Pricing of Reimbursable Medicines in the Retail Pharmacy Market Price Revisions Pricing Activity Drug Pricing Applications Submitted by Type, 2006 Average Number of Days Taken to Process First-Time Registrations, 2006 Pharmacy Margins Reference Pricing (TFR) Pricing of Hospital Medicines Reimbursement Distribution of the Pharmaceutical Market According to Reimbursement Rate, 2006 Intellectual Property Leading Active Ingredients Coming off Patent, 2005-2007 Supplementary Protection Certificates Generics in the French PPI Market PPIs on the French market, 2007 Reimbursable Sales of PPPIs (Régime Générale), 2002-2006 (Million Euros) Reimbursable Sales of PPPIs (Régime Générale), 2002-2006 (%) Reimbursable Sales of PPPIs (Régime Générale), 2002-2006 (Million Units) Reimbursable Sales of PPPIs (Régime Générale), 2002-2006 (%) Reimbursable Sales of PPPIs (Régime Générale), 2002-2006 (Average Unit Price, Euros) Reimbursable Sales of PPIs by Patent Status (Régime Générale), 2004-2006 (Million Euros) Reimbursable Sales of PPIs by Patent Status (Régime Générale), 2004-2006 (Million Units) Omeprazole and esomeprazole Omeprazole Sales Data (Régime Générale), 2004-2006 (Million Euros) Omeprazole Sales Data (Régime Générale), 2004-2006 (Million Units) Esomeprazole & Omeprazole Sales Data (Régime Générale), 2002-2006 (Million Euros) Esomepraole & Omeprazole Sales Data (Régime Générale), 2002-2006 (Million Units) Generics in the French Statins Market Statins on the French Market, 2007 Reimbursable Sales of Statins (Régime Générale), 2002-2006 (Million Euros) Reimbursable Sales of Statins (Régime Générale), 2002-2006 (%) Reimbursable Sales of Statins (Régime Générale), 2002-2006 (Million Units) Reimbursable Sales of Statins (Régime Générale), 2002-2006 (%) Average Unit Price of Statins (Régime Générale), 2002-2006 (Euros) Reimbursable Sales of Statins & Ezetimibe (Régime Générale), 2002-2006 (Million Euros) Reimbursable Sales of Statins by Patent Status (Régime Générale), 2005-2006 (Million Euros) Reimbursable Sales of Statins by Patent Status (Régime Générale), 2005-2006 (Million Units) Pravastatin Pravastatin Sales Data (Régime Générale), 2006 Simvastatin Simvastatin Sales Data (Régime Générale), 2005-2006 (000s Euros) Simvastatin Sales Data (Régime Générale), 2005-2006 (000s Units) Simvastatin + Ezetimibe Sales Data (Régime Générale), 2005-2006 (Million Euros) Simvastatin + Ezetimibe Sales Data (Régime Générale), 2005-2006 (Million Units). Directory Government Organisations Generic Trade Association Generic Manufacturers Italy Introduction Key Data Projections, 2007-2012 Healthcare System Organisation Health Expenditure Health Expenditure, 2000-2006 (Million Euros) Public Health Expenditure by Type, 2000-2006 (Million Euros) Public Health Expenditure by Region & Type, 2006 (Million Euros) Private Health Expenditure by Region, 1998-2003 (Million Euros) Healthcare Infrastructure Hospital Resources Inpatient Institutions by Type, 2000-2005 Inpatient Institutions by Region, 2000-2005 Hospital Beds by Type, 2005 Hospital Beds, 1997-2005 Hospital Beds by Region, 2005 Hospital Activity Hospital Activity, 2000-2004 Hospital Activity by Sector, 2004 Public Acute Hospital Activity by Region, 2004 Private Accredited Acute Hospital Activity by Region, 2004 Hospital Activity by Diagnosis Group, 2004 Ambulatory Resources Guardia Medica Points by Region, 2005 Ambulatory & Other Facilities, 2005 Ambulatory & Other Facilities by Type of Service, 2000-2005 Ambulatory Activity Clinical, Laboratory & Diagnostic Procedures, 2005 Medical Personnel Registered Doctors by Region, 2006 SSN Personnel, 2000-2005 Pharmaceutical Market Overview Size Summary of the Italian Pharmaceutical Market, 2007 Number of Pharmaceutical Products & Presentations, 2000-2006 Number of SSN Pharmaceutical Products & Presentations, 2000-2007 Projections Market Projections, 2007-2012 Local Manufacturers Generic Market Size Net SSN Sales by Patent Status, 2002-2006 (Million Euros) Net SSN Sales by Patent Status, 2002-2006 (%) Change in Net SSN Sales by Patent Status, 2003-2006 (%) Generics Sales as % of Net SSN Sales by Region, 2002-2006 Per Capita Net SSN Generics Expenditure by Region, 2002-2006 (Euros) Net SSN Generics Sales by Region, 2002-2006 (DDD/1,000 Population) Generics Sales as % of Net SSN Sales by Region, 2002-2006 (DDD/1,000 Population) Gross SSN Generics Sales by Leading Active Ingredient, 2006 (Million Euros) Gross SSN Generics Sales by Leading Active Ingredient, 2006 (DDD) Projections Projected Unbranded Generic Market, 2007-2012 Outlook SWOT Analysis of the Italian Generics Market, 2007 Domestic Production Leading Italian Generic Producers, 2007 Trade Association ASSOGENERICI Members of ASSOGENERICI, 2007 Local Manufacturers Angenerico Angelini’s Pharmaceutical Companies, 2006 DOC Generici Eurogenerici Eurogenerici’s Sales, 2002-2006 (Million Euros) Eurogenerici’s Sales, 2002-2006 (%) Eugenerici’s Sales as % of Stada’s Sales, 2002-2006 (%) Hexan Merck Generics Italia Merck Generics Italia’s Sales, 2004-2006 (Million Euros) Pliva Pharma Pliva Italia’s Sales, 2003-2005 (US$ Million) Ranbaxy ratiopharm Italia Sandoz Sandoz’s Italian Sales within the Novartis Group, 2004-2005 (Million Euros) Teva Pharma Italia Teva Pharma Italia’s Production Capabilities, 2006 Regulatory Environment Pricing & Reimbursement EU Directive on the Transparency of Pricing & Reimbursement Reimbursement Intellectual Property National Supplementary Protection Certificate Leading Active Ingredients with Patents Close to Expiry, 2007 Directory Government Organisations Generic Trade Associations Generic Manufacturers Portugal Introduction Key Data Projections, 2007-2012 Healthcare System Organisation Organic Health Law No. 10/1993 Health Regions, 1993 Decree Law No. 257/2001 Health Expenditure Projected Health Expenditure, 2006-2012 Health Expenditure, 2000-2005 (Million Euros) Healthcare Infrastructure Hospital Resources Public & Private Hospitals, 1990-2005 Public & Private Hospitals by Region, 2005 General & Specialty Hospitals by Type, 2005 Hospital Beds & Operating Rooms, 1990-2005 Hospital Activity Hospital Admissions, 1990-2005 Hospital Admissions by Region, 2005 Hospital Admissions by Hospital Type, 2005 Admissions, Discharges & Patient Days by Hospital Specialty, 2005 Hospital Consultations by Specialty, 1990-2005 (000s) Hospital Consultations by Specialty & Region, 2005 (000s) Hospitals Diagnostic Procedures, 2001-2005 Public & Private Hospitals Therapeutic Procedures, 2005 Outpatient Resources Outpatient Health Centres, Sub-Centres & Beds, 1990-2005 Outpatient Activity Outpatient Admissions & Days, 1990-2005 Outpatient Admissions & Days by Region, 2005 Outpatient Consultations by Specialty, 1990-2005 (000s) Medical Personnel Pharmaceutical Market Overview. Size Summary of the Portuguese Pharmaceutical Market at Retail Prices, 2007 Projections Market Projections, 2007-2012 Local manufacturers INFARMED’s Listed National Manufacturers, 2007 Generic Market Size Generics Pharmacy Sales by Value & Volume, 2003-2006 Generics Pharmacy Sales by Month, 2003-2006 (Million Euros) Generics Pharmacy Sales by Month, 2003-2006 (000 Units) Generics as a Percentage of the Pharmacy Sector by Volume, 2003-2006 Generics Pharmacy Sales by Therapeutic Area, 2006 (Million Euros) Generics Pharmacy Sales by Therapeutic Area, 2006 (Million Units) Generics Pharmacy Sales by Leading Active Ingredient, 2006 (Million Euros) Generics Pharmacy Sales by Leading Active Ingredient, 2006 (Million Units) Projections Projected Generics Market, 2007-2012 Outlook SWOT SWOT Analysis of the Portuguese Generics Market, 2007 Trade Association APOGEN Members of APOGEN, 2007 Domestic Production Leading Portuguese Generic Producers, 2007 Leading Generic Producers in the Pharmacy Sector, 2005 (%) Local Manufacturers Actavis Alter Bluepharma Ciclum Farma Ciclum Farma’s Sales, 2005-2006 (Million Euros) Generis Germed Hovione Labesfal Medinfar Merck Genéricos Ranbaxy ratiopharm Sandoz Tecnimede Tecnimede’s Financial Indicators, 2003-2007 Tecnimede’s Employees by Company, 2007 ToLife Winthrop Regulatory Environment Registration Market Authorisations of Generic Medicines in the Pharmacy Sector, 2004-2007 Change in Market Authorisations of Generic Medicines in the Pharmacy Sector, 2005-2007 (%) Market Authorisations of Generic Presentations, 2004-2007 Change in Market Authorisations of Generic Presentations, 2005-2007 (%) Pricing & Reimbursement Generics Presentations by Reimbursement Status & Price Range, 2005 Reimbursement EU Directive on the Transparency of Pricing & Reimbursement Reimbursements Generic Medicines by Reimbursement & Prescription Status, 2005 Generic Presentations by Reimbursement & Prescription Status, 2005 Generic Medicines & Presentations by Reimbursement Level, 2005 Generic Presentations by Reimbursement Level & Therapeutic Group, 2005 Intellectual Property European Supplementary Protection Certificate Organon Commences Tibolone Patent Infringement Litigation in Portugal Directory Government Organisations Generic Trade Association Generic Manufacturers Spain Introduction Key Data, 2007-2012 Healthcare System Organisation Health Cohesion & Quality Law Health Expenditure Projected Health Expenditure, 2007-2012 Healthcare Infrastructure Hospital Resources Hospitals by Provision & Region, 2006 Hospitals by Provision & Specialty, 2006 Hospitals, 1985-2006 Hospital Beds by Provision & Region, 2006 Hospital Beds by Provision & Specialty, 2006 Hospital Beds, 1985-2006 Hospital Activity Hospital Activity by Provision, 2005 Hospital Activity by Specialty, 2005 Hospital Discharges by Hospital Type & Specialty, 2005 Hospital Discharges, 1994-2005 Ambulatory Resources Primary Care Consultations, 1994 & 2003 Medical Personnel Registered Medical Personnel, 2000-2006 Practising Medical Personnel, 2006 Pharmaceutical Market Overview Size Summary of the Spanish Pharmaceutical Market, 2007 Projections Market Projections, 2007-2012 Local Manufacturers Leading Pharmaceutical Companies in Spain, 2006 Generic Market Size Generics Pharmacy Sales by Value & Volume, 2002-2006 Pharmacy Sales Value & Volume by Patent Status, 2006 SNS Pharmaceutical Sales by Patent Status, 2000-2005 (Million Euros) SNS Pharmaceutical Sales by Patent Status, 2000-2005 (%) Change in SNS Pharmaceutical Sales by Patent Status, 2000-2005 (%) SNS Pharmaceutical Sales by Patent Status, 2000-2005 (Million Units) SNS Pharmaceutical Sales by Patent Status, 2000-2005 (%) Change in SNS Pharmaceutical Sales by Patent Status, 2000-2005 (%) SNS Prescription Cost by Patent Status, 2000-2005 (Euros) Projections Projected Generics Market, 2007-2012 Outlook Biosimilars’ Substitution, Not a Viable Option in Spain Regional INN Prescribing Regional Generic Penetration The II Iberian Simposium on Generics Findings of the Study on Generics Perception, October 2005 SWOT SWOT Analysis of the Spanish Generics Market, 2007 Trade Association AESEG Members of AESEG, 2007 Local Manufacturers Leading Spanish Generic Producers, 2007 Companies with Generics in the Market, January 2007 Number of Companies with Generics in the SNS Market, 2000-2006 Companies by Number of Generics in the SNS Market, 2000-2006 Companies by Number of Generics in the SNS Market, 2006 Adamed Alter Alter’s Financial Indicators, 2005-2006 Barr Cantabria Pharma Cinfa Combino Pharm DOMAC Dr Reddy’s Kern Pharma Mabo-Farma Merck Normon Normon’s Financial Indicators, 1997-2006 Pharmagenus Ranbaxy Ranbaxy Spain’s Sales, 2004-2006 (US$ Million) ratiopharm Sandoz Novartis España’s Sales by Division, 2000-2005 (Million Euros) Novartis España’s Employees by Division, 2000-2005 Sandoz’s Leading Generics, 2005 Stada Laboratorio Stada’s Sales, 2003-2006 (Million Euros) Teva Regulatory Environment Registration Active Ingredients & Presentations of Generic Medicines, 2000-2006 Presentations by Patent Status, 2006 Presentations of Generic Medicines by Administration Type, 2000-2006 Presentations of Generic Medicines by Administration Type, 2000-2006 (%) Active Ingredients & Presentations of Generic Medicines by Therapeutic Area, 2006 Active Ingredients with the Highest Number of Generic Presentations, 2000-2006 Active Ingredients with the Highest Number of Presentations by Patent Status, 2006 Pricing & Reimbursement Co-Payments Co-Payments, 2006 RPS Analysis SNS Pharmaceutical Sales by the Reference Price System, 2005 (%) Generic Pricing Retail Prices of Presentations of Generic Medicines by Type, 2002-2006 (Euros) Intellectual property European Supplementary Protection Certificate Directory Government Organisations Generic Trade Association Generic Manufacturers

Summary:

The four EU countries analysed in this report - France, Italy, Portugal, Spain - are expected to deliver significant double digit growth over the next 5 years and present stable, regulated operating environments with excellent prospects. Key Areas Addressed: 5-year market forecasts to 2012 for the pharmaceutical and generic drug markets Analysis of market trends and outlook of key developments Domestic production and review of leading companies Regulatory environment Health provision and plans THIS REPORT ANSWERS KEY QUESTIONS Which therapy sector accounted for the greatest part of the Spanish generics market in 2006? What measures are in place to reduce generic prices in Portugal? How might developments in the French reference pricing system affect the generics market? What developments with supplementary protection certificates will positively affect the Italian generics market after 2010? What are the 8 leading active ingredients to lose patent protection in Italy in 2007? How has generic pravastatin fared in the French statin market against simvastatin? For a complete review of the market, prospects and competitive environment in these important generic drugs markets make sure you read this unique report.